PAI-1 (4G/5G) (plasminogen activator inhibitor-1)

The gene is present in the following complexes:

DNA diagnostics for a predisposition to pregnancy loss

It regulates fibrinolysis. An increase in the PAI-1 level during hypoxia leads to decreased fibrinolysis. The 4G/4G allelic variant is associated with habitual miscarriage and an increased risk of severe gestosis. Hypoxia, a developmental delay and intrauterine fetal demise. The decreased likelihood of embryo implantation during IVF in the case of 4G/4G homozygote.

Quantitative assessment of the genetic risk of cardiovascular diseases of various nosologies

It regulates fibrinolysis. An increase in the PAI-1 level during hypoxia leads to decreased fibrinolysis and the formation of a fibrin base for the growth of new blood vessels. One of the main components of the thrombolytic plasminogen-plasmin system plays an important role in establishing a predisposition to cardiovascular diseases. The 4G allele is associated with the risk of CVD development.

DNA diagnostics for a predisposition to high sporting achievements

One of the main components of the thrombolytic plasminogen-plasmin system. It regulates fibrinolysis. The 4G allele carriage leads to an increased gene expression and, consequently, to the increased PAI-1 level in blood, which leads to decreased fibrinolysis and the formation of a fibrin base for the growth of new blood vessels. The carriers of the PAI-1 gene 4G/4G genotype are characterized by a more significant increase in maximum oxygen consumption in response to physical exercise, training endurance, versus 5G/5G genotype carriers.